Los Angeles Capital Management’s Cabaletta Bio CABA Stock Holding History

Los Angeles Capital Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Buy	+34,419	New	+$113K	﹤0.01%	1333

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Los Angeles Capital Management's CABA Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Cabaletta Bio (CABA) in Q2 2026: 34,419 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #1333 among its holdings.

140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Los Angeles Capital Management held 34,419 shares of Cabaletta Bio worth $107K as of Q2 2026.
Cabaletta Bio was a new Los Angeles Capital Management position in Q2 2026.
Cabaletta Bio made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1333 holding.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.